Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bcl6 mediates CD8+ T cell fate decision in cancer

ABSTRACT: Bcl6 mediates CD8+ T cell fate decision in cancer

PROVIDER: PRJNA754285 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15440761.fastq.gz	Fastqsanger.gz
	SRR15440762.fastq.gz	Fastqsanger.gz
	SRR15440763_1.fastq.gz	Fastqsanger.gz
	SRR15440763_2.fastq.gz	Fastqsanger.gz
	SRR15440764_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Bcl6 regulates CD8+ T cell fate decision in cancer [RNA-Seq]

Project description:Bcl6 regulates CD8+ T cell fate decision in cancer [RNA-Seq]

| PRJNA754303 | ENA

Bcl6 regulates CD8+ T cell fate decision in cancer [ChIP-Seq]

Project description:Bcl6 regulates CD8+ T cell fate decision in cancer [ChIP-Seq]

| PRJNA754302 | ENA

Bcl6 regulates CD8+ T cell fate decision in cancer [RNA-Seq]

Project description:Overcoming CD8+ T cell "exhaustion" is critical in cancer immunotherapy. Intra-tumor CD8+ T cells contain stem-like (Texprog) and terminally differentiated (Texterm) subpopulations that mediate the persistence and potency of anti-tumor responses, respectively. How extrinsic signals via transcription factors control these two subsets are unclear. Previously, Bcl6 was shown to be selectively expressed by Texprog cells and promote their generation in chronic infection. Here, we found that in cancer, Bcl6 deficiency impacted, not the generation, but rather the persistence of Texprog cells, thus abrogating long-term tumor control. Bcl6 expression in CD8+ T cells is reciprocally regulated by TGF-?-SMAD2 and IL-2-STAT5 signaling pathways. Blimp1, regulated by IL-2 signaling, potently inhibited Bcl6 expression and its transcriptional activities; Prdm1 deficiency greatly improved the efficacy of anti-PD-1 therapy. Thus, we identified the TGF-?-Bcl6 and IL-2-Blimp1 antagonistic pathways in regulation of anti-tumor CD8+ T cells, which benefits cancer immunotherapy.

2023-08-15 | GSE182035 | GEO

Bcl6 regulates CD8+ T cell fate decision in cancer [ChIP-Seq]

2023-08-15 | GSE182034 | GEO

Bcl6 mediates CD8+ T cell fate decision in cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-08-15 | GSE182036 | GEO

Telomere Shortening Impairs PGC Fate Decision

Project description:Telomere Shortening Impairs PGC Fate Decision

| PRJNA660792 | ENA

BCL6 mediates Chemoresistance in Acute Myeloid Leukemia

Project description:BCL6 mediates Chemoresistance in Acute Myeloid Leukemia

| PRJNA549958 | ENA

In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ T cell fate decisions [microarray_dataset1]

Project description:The role of nutrient signaling processes in the fate decision of CD8 is incompletely understood. By performing in vivo pooled CRISPR-Cas9 screening, we uncovered nutrient signaling processes underpinning the dynamics and heterogeneity of CD8 T cell fate decisions.

2021-02-25 | GSE148681 | GEO

In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ T cell fate decisions [Pofut1_microarray]

2021-02-25 | GSE160225 | GEO

In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ T cell fate decisions [NICD_microarray]

2021-02-25 | GSE160218 | GEO